Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · IEX Real-Time Price · USD
18.66
-0.14 (-0.74%)
At close: Jul 19, 2024, 4:00 PM
18.65
-0.01 (-0.05%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Zai Lab Employees
Zai Lab had 2,175 employees as of December 31, 2023. The number of employees increased by 139 or 6.83% compared to the previous year.
Employees
2,175
Change (1Y)
139
Growth (1Y)
6.83%
Revenue / Employee
$133,826
Profits / Employee
-$155,838
Market Cap
1.85B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,175 | 139 | 6.83% |
Dec 31, 2022 | 2,036 | 85 | 4.36% |
Dec 31, 2021 | 1,951 | 757 | 63.40% |
Dec 31, 2020 | 1,194 | 502 | 72.54% |
Dec 31, 2019 | 692 | 383 | 123.95% |
Dec 31, 2018 | 309 | 221 | 251.14% |
Dec 31, 2017 | 88 | 36 | 69.23% |
Dec 31, 2016 | 52 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Warby Parker | 3,491 |
NeoGenomics | 2,100 |
Veracyte | 815 |
RxSight | 374 |
Mirum Pharmaceuticals | 264 |
Harmony Biosciences Holdings | 246 |
Neumora Therapeutics | 124 |
Verona Pharma | 79 |
ZLAB News
- 6 days ago - Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China - Business Wire
- 6 days ago - Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy - Business Wire
- 12 days ago - Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024 - Business Wire
- 12 days ago - Aldinger Company Acquires J&J Calibrations - Business Wire
- 5 weeks ago - Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D - Business Wire
- 2 months ago - Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis - Business Wire
- 2 months ago - Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China - Business Wire
- 2 months ago - Zai Lab Announces Participation in May and June Investor Conferences - Business Wire